These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 25246439)

  • 1. Clinical significance of 2 h plasma concentrations of first-line anti-tuberculosis drugs: a prospective observational study--authors' response.
    Prahl JB; Johansen IS; Cohen AS; Frimodt-Møller N; Andersen ÅB
    J Antimicrob Chemother; 2015 Jan; 70(1):321-2. PubMed ID: 25246439
    [No Abstract]   [Full Text] [Related]  

  • 2. Comment on: Clinical significance of 2 h plasma concentrations of first-line anti-tuberculosis drugs: a prospective observational study.
    Pasipanodya JG; Srivastava S; Gumbo T
    J Antimicrob Chemother; 2015 Jan; 70(1):320-1. PubMed ID: 25182065
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical significance of 2 h plasma concentrations of first-line anti-tuberculosis drugs: a prospective observational study.
    Prahl JB; Johansen IS; Cohen AS; Frimodt-Møller N; Andersen ÅB
    J Antimicrob Chemother; 2014 Oct; 69(10):2841-7. PubMed ID: 25140577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Food significantly reduces plasma concentrations of first-line anti-tuberculosis drugs.
    Kumar AKH; Chandrasekaran V; Kumar AK; Kawaskar M; Lavanya J; Swaminathan S; Ramachandran G
    Indian J Med Res; 2017 Apr; 145(4):530-535. PubMed ID: 28862186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Method for simultaneous analysis of nine second-line anti-tuberculosis drugs using UPLC-MS/MS.
    Han M; Jun SH; Lee JH; Park KU; Song J; Song SH
    J Antimicrob Chemother; 2013 Sep; 68(9):2066-73. PubMed ID: 23657802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Anti-tuberculosis drugs].
    Doi N
    Nihon Rinsho; 2007 Feb; 65 Suppl 2 Pt. 1():367-74. PubMed ID: 17455647
    [No Abstract]   [Full Text] [Related]  

  • 7. Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring.
    Verbeeck RK; Günther G; Kibuule D; Hunter C; Rennie TW
    Eur J Clin Pharmacol; 2016 Aug; 72(8):905-16. PubMed ID: 27305904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assuring bioavailability of fixed-dose combinations of anti-tuberculosis medications. A joint statement of the International Union Against Tuberculosis and Lung Diseases and the World Health Organization.
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S282-3. PubMed ID: 10593704
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacokinetics of anti-tuberculosis drugs in Venezuelan children younger than 16 years of age: supportive evidence for the implementation of revised WHO dosing recommendations.
    Verhagen LM; López D; Hermans PW; Warris A; de Groot R; García JF; de Waard JH; Aarnoutse RE
    Trop Med Int Health; 2012 Dec; 17(12):1449-56. PubMed ID: 23094704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics of moxifloxacin, cycloserine, p-aminosalicylic acid and kanamycin for the treatment of multi-drug-resistant tuberculosis.
    Chang MJ; Jin B; Chae JW; Yun HY; Kim ES; Lee YJ; Cho YJ; Yoon HI; Lee CT; Park KU; Song J; Lee JH; Park JS
    Int J Antimicrob Agents; 2017 Jun; 49(6):677-687. PubMed ID: 28408267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A UPLC-MS-MS method for the simultaneous quantification of first-line antituberculars in plasma and in PBMCs.
    Baietto L; Calcagno A; Motta I; Baruffi K; Poretti V; Di Perri G; Bonora S; D'Avolio A
    J Antimicrob Chemother; 2015 Sep; 70(9):2572-5. PubMed ID: 26066583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dosage of isoniazid and rifampicin poorly predicts drug exposure in tuberculosis patients.
    Sturkenboom MG; Akkerman OW; van Altena R; de Lange WC; Kosterink JG; van der Werf TS; Alffenaar JC
    Eur Respir J; 2016 Oct; 48(4):1237-1239. PubMed ID: 27492836
    [No Abstract]   [Full Text] [Related]  

  • 13. Therapeutic drug monitoring in the treatment of tuberculosis patients.
    Magis-Escurra C; van den Boogaard J; Ijdema D; Boeree M; Aarnoutse R
    Pulm Pharmacol Ther; 2012 Feb; 25(1):83-6. PubMed ID: 22179055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An interlaboratory quality control programme for the measurement of tuberculosis drugs.
    Aarnoutse RE; Sturkenboom MG; Robijns K; Harteveld AR; Greijdanus B; Uges DR; Touw DJ; Alffenaar JW
    Eur Respir J; 2015 Jul; 46(1):268-71. PubMed ID: 25882800
    [No Abstract]   [Full Text] [Related]  

  • 15. New anti-tuberculosis drugs in clinical trials with novel mechanisms of action.
    Rivers EC; Mancera RL
    Drug Discov Today; 2008 Dec; 13(23-24):1090-8. PubMed ID: 18840542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic efficacy of Poly(DL-lactide-Co-Glycolide)-encapsulated antitubercular drugs against Mycobacterium tuberculosis infection induced in mice.
    Dutt M; Khuller GK
    Antimicrob Agents Chemother; 2001 Jan; 45(1):363-6. PubMed ID: 11121000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Administration of antituberculous drugs to subjects with basic diseases. 1. Chemotherapy of tuberculosis in patients with impaired renal function].
    Usuta Y
    Kekkaku; 1987 Dec; 62(12):664-7. PubMed ID: 3448351
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in HIV-infected Indian children.
    Mukherjee A; Velpandian T; Singla M; Kanhiya K; Kabra SK; Lodha R
    Int J Tuberc Lung Dis; 2016 May; 20(5):666-72. PubMed ID: 27084822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization?
    Motta I; Calcagno A; Bonora S
    Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):59-82. PubMed ID: 29226732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fixed-dose combination formulations for tuberculosis treatment.
    Sbarbaro J; Blomberg B; Chaulet P
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S286-8. PubMed ID: 10593706
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.